[go: up one dir, main page]

DK2081950T3 - Med irinotecanbehandling forbundne ekspressionsprofiler - Google Patents

Med irinotecanbehandling forbundne ekspressionsprofiler

Info

Publication number
DK2081950T3
DK2081950T3 DK07867158.3T DK07867158T DK2081950T3 DK 2081950 T3 DK2081950 T3 DK 2081950T3 DK 07867158 T DK07867158 T DK 07867158T DK 2081950 T3 DK2081950 T3 DK 2081950T3
Authority
DK
Denmark
Prior art keywords
expression profiles
profiles associated
irinotecan treatment
irinotecan
treatment
Prior art date
Application number
DK07867158.3T
Other languages
English (en)
Inventor
Patrick J Muraca
Original Assignee
Nuclea Biomarkers Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers Llc filed Critical Nuclea Biomarkers Llc
Application granted granted Critical
Publication of DK2081950T3 publication Critical patent/DK2081950T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK07867158.3T 2006-09-21 2007-09-21 Med irinotecanbehandling forbundne ekspressionsprofiler DK2081950T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84629806P 2006-09-21 2006-09-21
US90643807P 2007-03-12 2007-03-12
PCT/US2007/020498 WO2008073177A2 (en) 2006-09-21 2007-09-21 Expression profiles associated with irinotecan treatment

Publications (1)

Publication Number Publication Date
DK2081950T3 true DK2081950T3 (da) 2013-06-03

Family

ID=39512250

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07867158.3T DK2081950T3 (da) 2006-09-21 2007-09-21 Med irinotecanbehandling forbundne ekspressionsprofiler

Country Status (5)

Country Link
US (3) US20080076134A1 (da)
EP (1) EP2081950B1 (da)
DK (1) DK2081950T3 (da)
ES (1) ES2405654T3 (da)
WO (1) WO2008073177A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059464A1 (en) * 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
WO2010062705A1 (en) * 2008-11-03 2010-06-03 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
CN102325905B (zh) * 2009-03-13 2014-07-16 株式会社益力多本社 伊立替康的敏感性判断方法及其利用
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US9459254B2 (en) * 2009-10-30 2016-10-04 Keio University Method for determining sensitivity to an anticancer agent
JP5548694B2 (ja) * 2009-10-30 2014-07-16 学校法人慶應義塾 抗がん剤の感受性の判定方法
EP2589665A4 (en) * 2010-06-29 2013-11-20 Univ Kurume METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON A CANCER PATIENTS AND THE METHOD AND KIT USED IN THE METHOD
US20140273273A1 (en) * 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
EP2881472A1 (en) 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
EP3302060B1 (en) * 2015-05-26 2020-02-12 Kaohsiung Medical University Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6350894A (en) * 1993-03-05 1994-09-26 Clifford W. Schweinfest Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
US6455251B1 (en) * 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
EP0847398A4 (en) * 1995-06-06 2003-02-05 Human Genome Sciences Inc COLON-SPECIFIC GENES AND PROTEINS
US6337195B1 (en) * 1995-06-06 2002-01-08 Human Genome Sciences, Inc. Colon specific genes and proteins
US6602659B1 (en) * 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
WO1999033963A1 (en) * 1997-12-31 1999-07-08 Chiron Corporation Metastatic cancer regulated gene
US6949339B1 (en) * 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
ATE386804T1 (de) * 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
US6773878B1 (en) * 1999-11-09 2004-08-10 Eos Biotechnology, Inc. Methods of diagnosing of colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
EP1167045A4 (en) * 1999-03-31 2007-07-11 Canon Finetech Inc PRINTER
US6455668B1 (en) * 2000-01-28 2002-09-24 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6566502B1 (en) * 2000-01-28 2003-05-20 Eos Biotechnology, Inc. Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US6682890B2 (en) * 2000-08-17 2004-01-27 Protein Design Labs, Inc. Methods of diagnosing and determining prognosis of colorectal cancer
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
EP1340818A1 (en) * 2002-02-27 2003-09-03 Epigenomics AG Method and nucleic acids for the analysis of a colon cell proliferative disorder
DK1918386T3 (da) * 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
AU2003235470A1 (en) * 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
WO2004066941A2 (en) * 2003-01-24 2004-08-12 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
ES2690168T3 (es) * 2003-06-24 2018-11-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
US20050227266A1 (en) * 2004-02-06 2005-10-13 Ross Douglas T Biomarker:compound correlations in cancer diagnosis and therapy
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US7794960B2 (en) * 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ATE550440T1 (de) * 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20070221273A1 (en) * 2006-03-22 2007-09-27 Landers Jerry L Valve for beverage dispenser

Also Published As

Publication number Publication date
US8580926B2 (en) 2013-11-12
ES2405654T3 (es) 2013-05-31
US20090047684A1 (en) 2009-02-19
WO2008073177A2 (en) 2008-06-19
US7763438B2 (en) 2010-07-27
EP2081950B1 (en) 2013-03-20
US20090298084A1 (en) 2009-12-03
WO2008073177A3 (en) 2008-11-06
EP2081950A4 (en) 2010-03-17
EP2081950A2 (en) 2009-07-29
US20080076134A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
DK2081950T3 (da) Med irinotecanbehandling forbundne ekspressionsprofiler
DK2215110T3 (da) Alfa-amylasevarianter med ændrede egenskaber
BRPI0910854A2 (pt) métodos de tratamento
BRPI0910259A2 (pt) métodos de tratamento de inflamação
DK2106215T3 (da) Brød med forhøjet arabinoxylo-oligosaccharid-indhold
DK2245130T3 (da) Ts23 -alpha-amylasevarianter med ændrede egenskaber
DK2479265T3 (da) Glucoamylasevarianter med ændrede egenskaber
DK2099453T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DK2035369T3 (da) Terapeutiske
DE502008000740D1 (de) Rollosystem
DK2173831T3 (da) Brøndbehandling
BRPI0818598A2 (pt) agentes terapêuticos - 802
HRP20160577T1 (hr) Liječenje osteoartritisa
DK1927646T3 (da) Odoriseringsmiddel med forbedret stabilitet
DK2246477T3 (da) Spunspæl med dobbelt t-form
PT3133396T (pt) Métodos de tratamento utilizando fármacos eliminadores de amoníaco
AT506770A3 (de) Walze
DK2054412T3 (da) Imino-imidazo-pyridinderivater med antitrombotisk virkning
DE102006028487B8 (de) Rollladenpanzer
FI20060555L (fi) Saunankiuas
ITMI20060187U1 (it) Catetere orientabile
ES1065966Y (es) Ladrillo perfeccionado
FIU20070195U0 (fi) Kaasunkäsittelylaitteisto
FI7219U1 (fi) Hoitopöytä
UA14838S (uk) Ванна гідромасажна